Office Phone

313-577-1245

Biography

Dr. Peter LeWitt has been a faculty member in the Neurology Department at Wayne State University School of Medicine since 1986 but has not previously practiced at the DMC Central Campus. A graduate of Brown University School of Medicine (and also awarded a M.Med.Sc. in Biochemical Pharmacology), his neurology residency training was at Stanford University School of Medicine. He completed fellowship training in experimental therapeutics at the National Institute of Neurological and Communicative Disorders. His neurological subspecialty has been in movement disorders. He has been a founding member of the Parkinson Study Group, an officer of the Movement Disorder Society, and is currently president of the Tremor Research Group. Dr. LeWitt has extensive experience in clinical trials for Parkinson’s disease and other neurological disorders, and his research interests have also included animal models and biomarkers of neurological disease, pharmacokinetic analysis, and gene therapy for Parkinson’s disease.

Training

Resident in Neurology Stanford University Medical Center, Stanford, CA 1977 - 1980 (Chief Resident 1979 - 1980)

Resident in Medicine, Philadelphia General Hospital, University of Pennsylvania Division, Philadelphia, PA 1975 - 1976

Education

Brown University: MD, 1971 - 1975
Brown University: M. Med.Sc. (Biochemical Pharmacology), 1971 - 1975

Fellowships

Research Fellow (Parkinson Disease and Movement Disorders), Experimental Therapeutics Branch, National Insititute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, 1980-1983

• LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med 2008;359:2468-76
• Ascherio A, LeWitt PA, Xu K, et al. Urate predicts slower rates of clinical decline in Parkinson disease. Arch Neurol 2009; 66:1460-8
• LeWitt PA, Li J, Lu M, et al. 3-Hydroxykynurenine and other biomarkers of Parkinson’s disease discovered by metabolomic analysis. Mov Disord 2013,28:1653-60
• Loeffler DA, LeWitt PA, Camp DM. Nocardia asteroides-induced movement abnormalities in mice: relevance for Parkinson’s disease? Mov Disord 2016; 31:1134-38
• LeWitt PA, Li J, Lu M, Guo L, et al. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology 2017; 88:862-9
• Niethammer M, Tang CC, LeWitt PA, et al. Long-term follow-up of AAV2-GAD gene therapy for Parkinson’s disease. JCI Insight 2017; 2(7):e90133. doi:.org/10.1172/jci.insight.90133
• Patel N, LeWitt PA, et al. Night-time sleep and daytime wakefulness improved with pimavanserin treatment of Parkinson disease psychosis. Clin Neuropharmacol 2018; 41:210-5
• LeWitt PA, et al. Efficacy and safety of CVT-301 (levodopa inhalation powder) on motor function during OFF periods in Parkinson’s disease patients: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2019; 18:145-54
• LeWitt PA, Lipsman N, Kordower JH. Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson’s disease. Mov Disord 2019; 34:1274-8
• LeWitt PA, Kymes S, Hauser RA. Parkinson disease and orthostatic hypotension in the elderly: recognition and management of risk factors for falls. Aging Dis 2020; 9: 11:679-91
• LeWitt PA, Aradi SD, Hauser RA, Rascol O. The challenge of developing adenosine A2a antagonists for Parkinson disease: istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord (in press, 2020)
• LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: motor and nonmotor. Parkinsonism Relat Disord (in press, 2020)

← Return to listing